Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (161-170 of 212) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lectureJoseph M Unger, Michael LeBlanc, John J Crowley, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
JCI Insight|July 5, 2022
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromesAmy F McLemore, Hsin-An Hou, Benjamin S Meyer, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2020
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 AbnormalitiesDavid A Sallman, John Barnard, Najla H Al Ali, et al.
Haematologica|March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureAziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)Eric Padron, Amy Dezern, Marcio Andrade-Campos, et al.
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Haematologica|July 10, 2012
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaSarah Abu Kar, Anna Jankowska, Hideki Makishima, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.
Pageof 22

Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lectureJoseph M Unger, Michael LeBlanc, John J Crowley, et al.
Plos One|August 23, 2013
The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemiaEra L Pogosova-Agadjanyan, Kenneth J Kopecky, Fabiana Ostronoff, et al.
JCI Insight|July 5, 2022
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromesAmy F McLemore, Hsin-An Hou, Benjamin S Meyer, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2020
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 AbnormalitiesDavid A Sallman, John Barnard, Najla H Al Ali, et al.
Haematologica|March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureAziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)Eric Padron, Amy Dezern, Marcio Andrade-Campos, et al.
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Haematologica|July 10, 2012
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaSarah Abu Kar, Anna Jankowska, Hideki Makishima, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.
Pageof 22